Pursuing new drug discovery modalities, including cell therapies and mid-sized molecules
First written in FY2018. 15 of 16 entries say "Advanced", first in FY2019-Q2. Latest entry: 2026-10-08.
1 other company's latest entry also says "Advanced".
- 2026-10-08AdvancedBusiness Alliances
「本IgG分解薬アセットは、Biohaven社のMoDE™（Molecular Degraders of Extracellular Proteins、細胞外タンパク分解薬）プラットフォームから創出された新規低分子薬です。」
細胞治療・ADC・RNA等に加え、細胞外タンパク分解薬プラットフォーム由来の新規低分子薬が開発モダリティとして示された。canonical thread自体は変更しない。 - FY2026AdvancedAnnual report
「In March this year, the company began a Phase I trial in Japan of the anti-L1CAM ADC ONO-7429 for solid tumors.」
The ADC candidate ONO-7429 advanced to a domestic Phase I trial, progressing the clinical development of a new drug discovery modality. - 2026-05-08AdvancedEarnings presentation
「In March 2026, we began a Phase I study in Japan of the anti-L1CAM ADC ONO-7429 for solid tumors.」
A candidate based on the ADC modality advanced to a domestic Phase I study. - FY2025AdvancedAnnual report
「* In October last year, the company entered into a license agreement with South Korea's LigaChem Biosciences for the antibody-drug conjugate (ADC) LCB97 for solid tumors, as well as a drug discovery collaboration agreement to create novel ADCs using the company's ADC platform. * In December last year, the company began a research collaboration with US-based Jorna Therapeutics on drug discovery using RNA-editing technology. * In March this year, the company entered into a drug discovery collaboration agreement with Riborna Biosciences Co., Ltd. to create RNA-targeted small-molecule drugs for central nervous system diseases.」
The company added partnerships involving new drug discovery modalities, including ADCs, RNA editing and RNA-targeted small molecules. - FY2025-H1AdvancedAnnual report
「In September this year, the company began a Phase I trial in Japan of the PD-1/CD19 bispecific antibody ONO-4915 in healthy adults. In October this year, it entered into a license agreement with South Korea's LigaChem Biosciences for the antibody-drug conjugate (ADC) LCB97 for solid tumors, as well as a drug discovery collaboration agreement to create novel ADCs using the company's ADC platform.」
The PD-1/CD19 bispecific antibody ONO-4915 advanced to a domestic Phase I trial, and the company also entered into agreements to license in ADC LCB97 and collaborate on its creation, advancing research and development in new modalities. - FY2024-Q3AdvancedAnnual report
「The company began a Phase I trial in the United States of the iPS cell-derived HER2 CAR-T cell therapy ONO-8250 for HER2-positive solid tumors.」
For ONO-8250, an iPS cell-derived HER2 CAR-T cell therapy licensed in from Fate Therapeutics, the company began a Phase I trial in the United States, advancing the clinical development of its cell therapy modality. - FY2023AdvancedAnnual report
「In June last year, the company entered into an agreement to expand its drug discovery collaboration with US-based Fate Therapeutics, originally signed in September 2018 to create iPS cell-derived chimeric antigen receptor (CAR)-T cell therapies, to also include the creation of iPS cell-derived chimeric antigen receptor (CAR)-NK cell therapies.」
In addition to expanding the scope of the partnership from CAR-T to CAR-NK, research and development advanced across multiple modalities, including epigenetic regulators, GPCRs, targeted protein degradation small molecules and AI drug discovery. - FY2023-Q2AdvancedAnnual report
「In June this year, the company entered into an agreement to expand its drug discovery collaboration with US-based Fate Therapeutics, originally signed in September 2018 to create iPS cell-derived chimeric antigen receptor (CAR)-T cell therapies, to also include the creation of iPS cell-derived chimeric antigen receptor (CAR)-NK cell therapies.」
The partnership was expanded to include the creation of CAR-NK cell therapies in addition to conventional CAR-T cell therapies, broadening the company's efforts in new drug discovery modalities. - FY2023-Q1AdvancedAnnual report
「※2: We started a Phase I study in the United States of the epigenetic regulator “ONO-2020” in patients with “neurodegenerative diseases.”」
The company began a Phase I trial in the United States of the epigenetic regulator ONO-2020, advancing the clinical development of a candidate product with a new mechanism of action. - FY2022AdvancedAnnual report
「In October last year, the company began a Phase I trial of the PD-1×CD3 bispecific antibody ONO-4685 in the United States for T-cell lymphoma. In September last year, it began a Phase I trial of the PD-1×CD3 bispecific antibody ONO-4685 in Europe for autoimmune diseases.」
The company began clinical trials in the United States and Europe for bispecific antibodies, a new drug discovery modality, expanding the development regions and target diseases. - FY2022-Q3AdvancedAnnual report
「*3: The company began a Phase I trial in Japan of the TGF-β inhibitor ONO-7122 for solid tumors. / *4: The company began a Phase I trial in Japan of the STING agonist ONO-7914 for solid tumors.」
The company began domestic Phase I trials of candidate products based on new drug discovery modalities, specifically a TGF-β inhibitor and a STING agonist. - FY2022-Q2AdvancedAnnual report
「In October this year, the company began a Phase I trial of ONO-4685 in the United States for T-cell lymphoma. In September this year, it began a Phase I trial of ONO-4685 in Europe for autoimmune diseases.」
For the bispecific antibody ONO-4685, the company began Phase I trials for new indications in the United States and Europe, expanding the development regions and target diseases for this new drug discovery modality. - FY2020AdvancedAnnual report
「In March this year, the company entered into a new drug discovery partnership agreement and option agreement with Swiss-based Numab to create multispecific antibodies in the field of cancer immunology.」
The company entered into a drug discovery collaboration agreement with Numab for a new biologic modality, multispecific antibodies. - FY2020-Q1AdvancedAnnual report
「The PD-1×CD3 bispecific antibody ONO-4685 has entered a Phase I trial in autoimmune diseases.」
The company began a Phase I trial of the PD-1×CD3 bispecific antibody ONO-4685 for autoimmune diseases, advancing its efforts in new drug discovery modalities to the clinical stage. - FY2019-Q2AdvancedAnnual report
「In September this year, the company entered into a drug discovery collaboration agreement with US-based Fate Therapeutics to create iPS cell-derived allogeneic CAR-T cell therapies for cancer. | The company | Fate Therapeutics | United States | Joint research on iPS cell-derived allogeneic CAR-T cell therapies | Research funding | Upfront payment | Royalties | From 2018.9 for 15 years after launch or the patent term, whichever is longer」
The company entered into a joint research and drug discovery collaboration agreement with Fate Therapeutics for iPS cell-derived allogeneic CAR-T cell therapies, giving concrete form to its efforts in new drug discovery modalities. - FY2018First statedAnnual report
「In addition to strengthening drug discovery based on conventional small molecules and antibodies, we will also pursue drug discovery using new modalities such as cell therapies and mid-sized molecules.」
For the first time, the company explicitly identified as a standalone theme its policy of adopting cell therapies and mid-sized molecules as new drug discovery modalities alongside conventional small-molecule and antibody drug discovery.